Affiliations 

  • 1 Department of Obstetrics and Gynecology, Haukeland University Hospital, University of Bergen, Bergen, Norway
  • 2 Instituto Chileno de Medicina Reproductiva, Santiago, Chile
  • 3 Centre d'Atèncio Primària, EBA Centelles, Barcelona, Spain
  • 4 Medicus, Clinical Trials, Trondheim, Norway
  • 5 Perinatal HIV Research Unit, Baragwanath Hospital, Johannesburg, South Africa
  • 6 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 7 Kentucky Pediatric and Adult Research, Bardstown
  • 8 G-CENTRUM Olomouc, Olomouc, Czech Republic
  • 9 Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
  • 10 Sabah Woman's and Children's Hospital, Hospital Likas, Sabah, Malaysia
  • 11 Centrum Ambulantní, Brno, Czech Republic
  • 12 Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Republic of Korea
  • 13 Women's Research Center of Redlands, Terracina Medical Center, Redlands, California
  • 14 Assaf-Harofeh Medical Center, Zerifin, Israel
  • 15 Hacettepe Üniversitesi Beytepe Kampüsü, Ankara, Turkey
  • 16 Merck & Co Inc, Kenilworth, New Jersey
JAMA, 2016 12 13;316(22):2411-2421.
PMID: 27893068 DOI: 10.1001/jama.2016.17615

Abstract

Human papillomavirus (HPV) infections cause anogenital cancers and warts. The 9-valent HPV vaccine provides protection against 7 high-risk types of HPV responsible for 90% of cervical cancers and 2 other HPV types accounting for 90% of genital warts.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.